Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2025 08:00 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Remedy Plan has raised an $18M insider round to advance their lead asset, RPT1G, into a Phase 1/2 clinical trial in patients with AML and high-risk MDS
December 18, 2024 08:30 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
November 03, 2022 15:00 ET | Source: Roots Analysis

The NAMPT inhibitors market is projected to grow at an annualized rate of 15.08% during the period 2029-2040, claims Roots Analysis

London, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “NAMPT Inhibitors Market, 2022-2040” report to its list of offerings Cancer is one of the leading causes of...